Moberg Pharma completes a directed share issue of SEK 60 million for continued expansion

Moberg Pharma AB (publ) (”Moberg Pharma” or the “company”, OMX:MOB) today
announces that the company has completed a directed share issue of 2.1 million
new shares, which brings SEK 60 million to the company before transaction costs.
The new share issue, which was resolved by the Board of the company on May 27th,
2014 with authorization from the Annual General Meeting on May 13th, 2014,
includes 2,068,965 new shares and has been directed to a limited group of
Swedish and international institutional qualified investors at a price of SEK 29
per share through a private placement procedure.

The proceeds from the directed share issue strengthens Moberg Pharma’s balance
sheet and enables value-creating investments, including acquisitions of
additional brands/products as well as preparations for licensing and development
of product candidates in clinical phase.

“We are very pleased with the interest for the new share issue and welcome our
new shareholders. The new issue strengthens Moberg Pharma’s financial position
and enables further investments with focus on acquisitions of established
products for our U.S. operations. In the last 18 months we have completed three
deals. Continued M&A activity in an integral element of our strategy”, comments
Peter Wolpert, CEO of Moberg Pharma.

The reasons for the deviation from the shareholders’ pre-emptive rights are that
the Board of the company deems it beneficial for the company and the
shareholders to expand the company´s institutional shareholder base, but also to
capitalize on the opportunity to raise new capital to the company at attractive
terms.

The subscription price has been set through a customary bookbuilding process.
The subscription price entails a discount of approximately 7.3 percent in
relation to the average daily price for the last 30 trading days as of the last
day of trading before the decision to issue the new shares.

The new share issue in Moberg Pharma increases the number of shares with
2,068,965 shares from 11,893,572 shares to 13,962,537 shares in total and
increases the share capital by SEK 206,896.50 from SEK 1,189,357.20 to SEK
1,396,253.70 in total. The new share issue entails a dilution of approximately
15 percent.

Östersjöstiftelsen, the largest shareholder of the company, has in connection
with the new issue lent 2,068,965 shares to ABG Sundal Collier to enable
delivery of subscribed shares to investors. The lent out shares will be returned
after registration of the share issue with the Swedish Companies Registration
Office (Sw. Bolagsverket).

Prospectus:
The company will publish a prospectus in connection with the admission to
trading of the shares issued in the new share issue. The complete prospectus is
expected to be available on Moberg Pharma’s website (www.mobergpharma.se) on or
about June 17th, 2014.

Advisors:
ABG Sundal Collier acted as Joint Lead Manager and Sole Bookrunner, HDR Partners
acted as Joint Lead Manager and Advokatfirman Lindahl acted as legal advisor to
Moberg Pharma in connection with the new share issue.

About this information
The information provided herein is such that Moberg Pharma is required to
disclose pursuant to the Swedish Securities Markets Act and/or the Swedish
Financial Instruments Trading Act. The information was submitted for publication
at 8.00 am (CET) on May 28th, 2014.

Important information
Publication or distribution of this press release in certain jurisdictions may
be subject to restrictions according to law and the people in jurisdictions
where this press release has been made public or distributed should inform
themselves and follow such local restrictions. This press release does not
contain and does not constitute or form part of an invitation to acquire or
subscribe or a solicitation of any offer to buy or subscribe for shares,
subscription rights or other securities in Moberg Pharma.

This press release may not be published or distributed, directly or indirectly,
in or into the U.S., Canada, Japan, Hong Kong, New Zeeland, South Africa,
Australia or in any other jurisdiction where such distribution would be
prohibited by applicable law. The information in this press release may not be
redistributed, reproduced or passed on in ways that conflict with applicable
restrictions. Failure to comply with these restrictions may constitute a
violation of the United States Securities Act of 1933 (“Securities Act”) or
applicable laws of other jurisdictions.

Forward-looking statements
This press release contain certain forward-looking statements that reflect the
company’s current view and expectations of future events and financial and
operational performance, including statements regarding the directed share issue
and statements regarding guidance, planning, outlook and strategies. Words such
as "intends", "anticipates", "expects", "plan ", "anticipate", “can” or similar
expressions regarding indications or predictions of future developments or
trends, and are not based on historical facts, constitute forward-looking
information. Although the company believes that these statements are based upon
reasonable assumptions and expectations, the company cannot guarantee that such
statements will be realized. Forward-looking statements are inherently
associated with both known and unknown risks and uncertainties and future
results or developments may differ materially from those set forth in forward
-looking information. Forward-looking statements in the press release are only
valid on the date of the press release and are subject to change without notice.
The company undertakes no obligation to publicly update or revise any forward
-looking statements as a result of new information or future events, other than
as required by applicable law or stock market regularization.
For additional information, please contact:
Peter Wolpert, CEO, Moberg Pharma AB, Phone: +46 707 35 71 35, e-mail:
peter.wolpert@mobergpharma.se
Peter Östling, IR, Moberg Pharma AB, Phone: +46 76 301 09 78, e-mail:
peter.ostling@mobergpharma.se
About Moberg Pharma
Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with
a direct sales and marketing organization in the U.S. and an extensive
distributor network in more than 40 countries. The company’s OTC portfolio
includes the brands Kerasal®, Jointflex®, Kerasal Nail™, Domeboro®, Vanquish®,
and Fergon®. Kerasal Nail™ (Nalox™ in certain ex-U.S. markets) is the leading
product for the treatment of nail disorders in the U.S. and Nordic market. The
current portfolio will be supplemented by the acquisition and in-licensing of
additional products as well as product development with a focus on innovative
drug delivery of proven compounds. Moberg Pharma has offices in Stockholm and
New Jersey and the company’s shares (OMX: MOB) are listed on the Small Cap list
of the NASDAQ OMX Nordic Exchange Stockholm. For further information, please
visit: www.mobergpharma.com.